Richard L Eckert
15PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (15)
Sort by Publication Date:
|May 25, 2023
Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype.Xi Chen, Gautam Adhikary, John J Newland
|Mar 30, 2023
Natural killer cells suppress human cutaneous squamous cell carcinoma cancer cell survival and tumor growth.Gautam Adhikary, Erica L Heipertz, Maja Preradovic
|Dec 23, 2022
Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.Gautam Adhikary, Suruchi Shrestha, Warren Naselsky
|Oct 26, 2022
Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotype.Xi Chen, Gautam Adhikary, Emily Ma
|Jul 18, 2022
The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.Xi Chen, Gautam Adhikary, John J Newland
|Mar 23, 2022
Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.Warren Naselsky, Gautam Adhikary, Suruchi Shrestha
Pageof 3
